Verastem, Inc. last reported quarterly results on Oct 14, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $24.0 million (+113.6% year over year) and diluted EPS of -$0.74. It usually reports 14–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 3, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 14–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 14, 2026
14 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
24
+113.6%
|
-75
+24.2%
|
-0.74
+45.2%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
40
+1775.4%
|
-35
-33.7%
|
-0.35
+43.5%
|
|
Feb 4, 2026
35 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
18
|
-33
+49.0%
|
-0.39
+70.2%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
11
+12.4%
|
-99
-311.1%
|
-1.35
-125.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
|
-65
-135.9%
|
-1.33
|
|
Feb 2, 2023
33 days after quarter end
|
—
ended Dec 31, 2022
|
—
|
—
|
—
|
|
Aug 8, 2022
39 days after quarter end
|
—
ended Jun 30, 2022
|
—
|
—
|
—
|
|
Aug 10, 2020
41 days after quarter end
|
—
ended Jun 30, 2020
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VSTM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Needham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1526119
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.